Table 1 The characteristics of study population
Group A NAs treatment pre-pregnancy (n=24) | Group B discontinue treatment (n=88) | Group C retreatment (n=22) | Group A vs B P1 value | Group A vs C P2 value | Group B vs C P3 value | |
|---|---|---|---|---|---|---|
Age, year | 29.8 (25.1–37.9) | 29.0 (20.0–37.0) | 29.0 (24.0–36.0) | 0.098 | 0.428 | 0.458 |
Parity, n (%) | 9 (37.5%) | 17 (19.3%) | 7 (31.8%) | 0.099 | 0.763 | 0.249 |
HBeAg positive, n (%) | 12 (50.0%) | 86 (97.7%) | 22 (100.0%) | < 0.001 | < 0.001 | 1.000 |
TDF treatment, n (%) | 19 (79.2%) | 42 (47.7%) | 16 (72.7%) | 0.010 | 0.734 | 0.055 |
Follow-up, month * | 37.0 (9.8–89.9) | 11.0 (0.5–73.0) | 25.0 (10.3–53.7) | < 0.001 | 0.013 | 0.005 |
ALT, U/L | 16.5(11.0–50.0) | 32.5 (18.0–116.0) | 102.5 (32.0–410.0) | < 0.001 | < 0.001 | < 0.001 |
HBsAg, log IU/mL | 3.10 (2.40–4.20) | 4.57 (2.94–5.01) | 4.60 (3.50–5.12) | < 0.001 | < 0.001 | 0.969 |
HBeAg, log PEIU/mL | 0.20 (0.00–2.47) | 2.97 (0.00–3.38) | 3.25 (1.11–3.71) | < 0.001 | < 0.001 | 0.030 |
HBV-DNA, log IU/mL | 0.00 (0.00–3.10) | 3.00 (0.00–4.46) | 6.90 (4.70–8.53) | < 0.001 | < 0.001 | < 0.001 |
Δ ALT，U/L | 0.0 (−27.0–36.0) | 5.0 (−208–73.0) | 84.5 (19.0–401.0) | 0.937 | < 0.001 | < 0.001 |
Δ HBsAg, log IU/mL | −0.02 (−0.20–2.36) | −0.14 (−0.69–0.92) | 1.30 (0.20–4.70) | 0.020 | < 0.001 | < 0.001 |
Δ HBeAg, PEIU/mL | 0.00 (−0.04–2.47) | −0.07 (−0.62–1.73) | 3.11 (−2.67–3.52) | 0.001 | < 0.001 | < 0.001 |
Δ HBV-DNA, log IU/mL | 0.00 (0.00–3.10) | −4.32 (−8.29–0 .00) | 6.8 (4.70–8.50) | < 0.001 | < 0.001 | < 0.001 |